秋霞电影在线观看,欧美成人aⅴ视频网站,人人妻人人妻人人片色AV,沈阳45老熟女高潮喷水亮点,ass新版ass毛茸茸pics

產品中心 PRODUCT
推薦產(chan)品 / Products
發布時間: 2017 - 03 - 16
發(fa)布時間: 2017 - 03 - 16
發布時間: 2017 - 03 - 16
租車常識 KNOWLEDGE
Case / 成(cheng)功案例(li)
說明: 數據來源:青島(dao)大(da)學(xue)(xue)(xue)醫(yi)學(xue)(xue)(xue)院(yuan)(yuan)附屬醫(yi)院(yuan)(yuan)復旦大(da)學(xue)(xue)(xue)附屬中山醫(yi)院(yuan)(yuan)上海交(jiao)通大(da)學(xue)(xue)(xue)醫(yi)學(xue)(xue)(xue)院(yuan)(yuan)附屬瑞金(jin)醫(yi)院(yuan)(yuan)數據統計:上海交(jiao)通大(da)學(xue)(xue)(xue)基(ji)礎醫(yi)學(xue)(xue)(xue)院(yuan)(yuan)生物統計教研室(shi)
說(shuo)明: 數據(ju)來源:國家食(shi)品藥(yao)品監督(du)管理(li)局濟南(nan)醫療器械質量監督(du)檢驗中心陰性(xing)(xing)組:小鼠背(bei)部皮(pi)下注(zhu)射PBS(PH7.2)實驗組:小鼠背(bei)部植(zhi)(zhi)入深凍骨對照組:小鼠背(bei)部植(zhi)(zhi)入已上市(shi)凍干骨體液免疫研究炎癥細胞因子含量特(te)異性(xing)(xing)細胞免疫反應NK細胞的活性(xing)(xing)
案例名稱: 病例二
說明(ming): 徐**,男性,于2006年2月24日(ri)因第3/4頸椎椎間盤突出(chu)癥,頸椎前路椎間盤切除,同種異(yi)體骨(gu)椎體間植骨(gu)融合內固(gu)定(ding)手術(shu),術(shu)后2個月,11個月及4年半(ban)隨(sui)訪(fang)植骨(gu)塊愈合良好(hao)
案例名(ming)稱: 病(bing)例一(yi)
說明(ming): 王*,女性,因右股(gu)骨骨囊腫,于2005年(nian)(nian)11月行囊腫刮除(chu)(chu),同種(zhong)異體骨顆粒植入(ru),股(gu)骨近端(duan)DHS鋼板螺釘內(nei)固(gu)定術(shu)后(hou),術(shu)后(hou)1年(nian)(nian)和2年(nian)(nian)隨訪(fang),骨愈(yu)合良好,內(nei)固(gu)定拔除(chu)(chu)。

組織工程(cheng)化骨修(xiu)復材(cai)料臨床應(ying)用問題與對策

日期(qi): 2017-05-04
瀏覽次(ci)數: 362

摘要 ?合成(cheng)材(cai)料(liao)組(zu)織(zhi)工程骨(gu)移(yi)植(zhi)(zhi)物是當前骨(gu)移(yi)植(zhi)(zhi)材(cai)料(liao)研發(fa)(fa)(fa)重(zhong)點(dian),發(fa)(fa)(fa)展迅速,但是,目(mu)(mu)前研發(fa)(fa)(fa)的各類(lei)支(zhi)架(jia)材(cai)料(liao)性(xing)能存在(zai)缺陷(xian),還不(bu)能完全(quan)滿足臨(lin)(lin)床要(yao)求;細胞(bao)體(ti)外篩選(xuan)、擴增(zeng)、分(fen)化(hua)和(he)為能在(zai)局部持續釋放細胞(bao)因子而采用的轉基因細胞(bao)移(yi)植(zhi)(zhi)或腺病毒轉染局部細胞(bao)等(deng)(deng)技術(shu)還存在(zai)安全(quan)隱患,回(hui)植(zhi)(zhi)體(ti)內后不(bu)能保(bao)證細胞(bao)活(huo)性(xing),細胞(bao)骨(gu)組(zu)織(zhi)工程種植(zhi)(zhi)體(ti)構建質量、及(ji)時性(xing),儲存、運(yun)輸等(deng)(deng)方面還不(bu)具(ju)臨(lin)(lin)床規(gui)模(mo)化(hua)應用的可行性(xing)。目(mu)(mu)前,無(wu)細胞(bao)人工合成(cheng)材(cai)料(liao)在(zai)臨(lin)(lin)床上脊柱融合、良(liang)性(xing)骨(gu)腫瘤(liu)刮除(chu)后填充等(deng)(deng)方面應用較(jiao)普遍,細胞(bao)骨(gu)組(zu)織(zhi)工程移(yi)植(zhi)(zhi)物應用僅見(jian)于(yu)散在(zai)病例報道。


關鍵詞 ?骨組織工程;支架;干細胞;細胞因子;

臨床(chuang)上(shang)嚴(yan)重(zhong)創(chuang)傷、腫瘤切(qie)除、骨(gu)(gu)(gu)感染、骨(gu)(gu)(gu)壞死等(deng)原因(yin)導致的(de)(de)(de)(de)的(de)(de)(de)(de)骨(gu)(gu)(gu)缺(que)損、骨(gu)(gu)(gu)折(zhe)不愈合(he)以及人工(gong)假體(ti)(ti)置換及翻(fan)修、脊柱(zhu)、關節融合(he)等(deng)十分常見(jian),自體(ti)(ti)皮質(zhi)-松質(zhi)骨(gu)(gu)(gu)移(yi)植(zhi)仍是(shi)無法被替代的(de)(de)(de)(de)“金(jin)標準”,但(dan)是(shi),存在諸(zhu)如供區新的(de)(de)(de)(de)創(chuang)傷、感染、疼痛等(deng)并發癥,特別是(shi),來源有(you)限(xian)不能(neng)滿(man)(man)足臨床(chuang)需要,因(yin)此,同種異(yi)體(ti)(ti)骨(gu)(gu)(gu)以較(jiao)好的(de)(de)(de)(de)骨(gu)(gu)(gu)傳(chuan)導、誘導性(xing),成為(wei)(wei)繼自體(ti)(ti)骨(gu)(gu)(gu)移(yi)植(zhi)之后的(de)(de)(de)(de)首選[1],但(dan)是(shi),來源仍然有(you)限(xian),其他缺(que)陷如:新鮮(xian)異(yi)體(ti)(ti)移(yi)植(zhi)存在疾病(bing)傳(chuan)播、免疫排斥和(he)難以保存等(deng)問題;深低(di)溫或(huo)凍干(gan)處理(li)可降(jiang)低(di)免疫原性(xing)和(he)疾病(bing)傳(chuan)染,但(dan)成骨(gu)(gu)(gu)誘導性(xing)能(neng)降(jiang)低(di);異(yi)體(ti)(ti)脫(tuo)鈣骨(gu)(gu)(gu)(demineralized bone matrix ,DBM)的(de)(de)(de)(de)骨(gu)(gu)(gu)誘導性(xing)也較(jiao)差,并受加工(gong)方法和(he)供體(ti)(ti)年(nian)齡等(deng)因(yin)素的(de)(de)(de)(de)影響等(deng)。在自體(ti)(ti)和(he)異(yi)體(ti)(ti)骨(gu)(gu)(gu)越來越不能(neng)滿(man)(man)足臨床(chuang)需要的(de)(de)(de)(de)的(de)(de)(de)(de)情(qing)況下,組織工(gong)程化骨(gu)(gu)(gu)人工(gong)合(he)成材料的(de)(de)(de)(de)研發與(yu)應用成為(wei)(wei)重(zhong)點。


1. 組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程化(hua)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)修(xiu)(xiu)復(fu)材料的(de)(de)(de)(de)臨床(chuang)(chuang)應用現(xian)狀 ?器官的(de)(de)(de)(de)組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程的(de)(de)(de)(de)一般技術(shu)路線(xian)是(shi)在(zai)體(ti)(ti)(ti)外(wai)(wai)(wai)用支(zhi)(zhi)架、種(zhong)(zhong)(zhong)(zhong)子細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)、細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)活(huo)(huo)性(xing)因子有(you)(you)機結合(he)(he)(he),構(gou)建(jian)有(you)(you)生命(ming)的(de)(de)(de)(de)種(zhong)(zhong)(zhong)(zhong)植(zhi)(zhi)(zhi)(zhi)體(ti)(ti)(ti),植(zhi)(zhi)(zhi)(zhi)入缺(que)損(sun)(sun)部位(wei)(wei)(wei),以替(ti)代(dai)病損(sun)(sun)組(zu)(zu)(zu)(zu)(zu)織(zhi)器官,恢復(fu)正(zheng)常(chang)的(de)(de)(de)(de)生理(li)結構(gou)和(he)(he)功(gong)(gong)(gong)能。骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)組(zu)(zu)(zu)(zu)(zu)織(zhi)結構(gou)、生化(hua)代(dai)謝和(he)(he)生理(li)功(gong)(gong)(gong)能相對較(jiao)簡(jian)單,與(yu)軟(ruan)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)、肌(ji)腱、神(shen)經等(deng)(deng)(deng)(deng)組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程再(zai)造(zao)相比,骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程又具(ju)有(you)(you)一定的(de)(de)(de)(de)特殊(shu)性(xing),其種(zhong)(zhong)(zhong)(zhong)植(zhi)(zhi)(zhi)(zhi)體(ti)(ti)(ti)的(de)(de)(de)(de)構(gou)建(jian)除(chu)經典的(de)(de)(de)(de)支(zhi)(zhi)架+細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)+細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)活(huo)(huo)性(xing)因子模(mo)式外(wai)(wai)(wai),還(huan)有(you)(you)支(zhi)(zhi)架+細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)和(he)(he)支(zhi)(zhi)架+細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)活(huo)(huo)性(xing)因子等(deng)(deng)(deng)(deng)。從(cong)1965年Urist發現(xian)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)形態(tai)發生蛋白質(zhi)(zhi)(Bone Morphogenetic Protein,BMP),40年來(lai)研(yan)究者著力構(gou)建(jian)了承載(zai)BMP的(de)(de)(de)(de)緩釋系統(Drug Delivery ? 作者單位(wei)(wei)(wei): 200025 上海交通大學(xue)(xue)醫學(xue)(xue)院瑞金(jin)醫院骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)科上海市傷(shang)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)科研(yan)究所(suo) ?基金(jin)項目(mu): ? 上海市“登山計劃”,No.06DZ220202 System,DDS),這種(zhong)(zhong)(zhong)(zhong)支(zhi)(zhi)架+細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)活(huo)(huo)性(xing)因子植(zhi)(zhi)(zhi)(zhi)入體(ti)(ti)(ti)內后(hou)(hou),局部持(chi)續(xu)釋放BMP,作用于(yu)隨血(xue)管和(he)(he)肉芽長(chang)入的(de)(de)(de)(de)基質(zhi)(zhi)干(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)和(he)(he)血(xue)液中骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)髓干(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao),誘(you)導(dao)成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)促進(jin)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)修(xiu)(xiu)復(fu)。學(xue)(xue)者將這種(zhong)(zhong)(zhong)(zhong)無(wu)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)種(zhong)(zhong)(zhong)(zhong)植(zhi)(zhi)(zhi)(zhi)體(ti)(ti)(ti)歸為廣義組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)范疇,而且后(hou)(hou)者省掉了細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)分離培養(yang)、復(fu)合(he)(he)(he)等(deng)(deng)(deng)(deng)復(fu)雜環(huan)節(jie),不涉及細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)移植(zhi)(zhi)(zhi)(zhi)的(de)(de)(de)(de)倫理(li)學(xue)(xue)問題,生產、保存、運(yun)輸方便,更貼近臨床(chuang)(chuang)規模(mo)化(hua)應用,成(cheng)(cheng)(cheng)為骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程的(de)(de)(de)(de)重要補充。 ? ? ? 無(wu)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)人工(gong)材料普遍用于(yu)良(liang)(liang)性(xing)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)瘤(liu)刮除(chu)后(hou)(hou)填(tian)充和(he)(he)脊柱融(rong)合(he)(he)(he)等(deng)(deng)(deng)(deng) [2、3] ;細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)型組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu) 在(zai)2001年后(hou)(hou)陸(lu)續(xu)應用于(yu)臨床(chuang)(chuang)。Vacanti用羥基磷灰石(shi)支(zhi)(zhi)架(hydroxyapatite scaffolds,HAS)復(fu)合(he)(he)(he)經過體(ti)(ti)(ti)外(wai)(wai)(wai)擴(kuo)增(zeng)(zeng)的(de)(de)(de)(de)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)膜細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)后(hou)(hou),立(li)即植(zhi)(zhi)(zhi)(zhi)入體(ti)(ti)(ti)內修(xiu)(xiu)復(fu)再(zai)造(zao)外(wai)(wai)(wai)傷(shang)性(xing)缺(que)失的(de)(de)(de)(de)拇指遠(yuan)節(jie)指骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)[4],證(zheng)(zheng)明(ming)(ming)了此(ci)(ci)方法臨床(chuang)(chuang)有(you)(you)效性(xing);Quarto等(deng)(deng)(deng)(deng)[5]體(ti)(ti)(ti)外(wai)(wai)(wai)培養(yang)擴(kuo)增(zeng)(zeng)自(zi)體(ti)(ti)(ti)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)髓基質(zhi)(zhi)干(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bone mesenchymal stem cells ,BMSCs),與(yu)HAS復(fu)合(he)(he)(he)構(gou)建(jian)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)+支(zhi)(zhi)架移植(zhi)(zhi)(zhi)(zhi)物,立(li)刻植(zhi)(zhi)(zhi)(zhi)入4-8cm骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)干(gan)缺(que)損(sun)(sun)處,證(zheng)(zheng)明(ming)(ming)對大骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)缺(que)修(xiu)(xiu)復(fu)有(you)(you)促進(jin)作用,7年隨訪(fang)效果(guo)滿意;柴崗等(deng)(deng)(deng)(deng)[6]等(deng)(deng)(deng)(deng)用自(zi)體(ti)(ti)(ti)BMSCs復(fu)合(he)(he)(he)DBM修(xiu)(xiu)復(fu)頜(he)面部骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)缺(que)損(sun)(sun)成(cheng)(cheng)(cheng)功(gong)(gong)(gong);楊志明(ming)(ming)等(deng)(deng)(deng)(deng)[7]用異體(ti)(ti)(ti)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)膜復(fu)合(he)(he)(he)支(zhi)(zhi)架修(xiu)(xiu)復(fu)多部位(wei)(wei)(wei)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)缺(que)損(sun)(sun)、骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)不連取得良(liang)(liang)好效果(guo);Warnke等(deng)(deng)(deng)(deng)[8、9]利用鈦合(he)(he)(he)金(jin)網填(tian)充牛骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)松質(zhi)(zhi)顆粒,復(fu)合(he)(he)(he)自(zi)體(ti)(ti)(ti)BMSCs、BMP-7和(he)(he)Ⅰ型膠原(collagen type-Ⅰ)后(hou)(hou)立(li)刻植(zhi)(zhi)(zhi)(zhi)入背闊(kuo)肌(ji)袋中使血(xue)管化(hua),7W后(hou)(hou)二次移植(zhi)(zhi)(zhi)(zhi)到下(xia)頜(he)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)缺(que)損(sun)(sun)處,成(cheng)(cheng)(cheng)功(gong)(gong)(gong)再(zai)造(zao)下(xia)頜(he)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu);Kitoh等(deng)(deng)(deng)(deng)[10]報(bao)道(dao)在(zai)用牽張成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)方法來(lai)治療2例(li)軟(ruan)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)發育(yu)不良(liang)(liang)、1例(li)先天性(xing)脛骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)假關節(jie)遺留下(xia)肢(zhi)不等(deng)(deng)(deng)(deng)長(chang)(3個(ge)股(gu)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)、2個(ge)脛骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu))時(shi),在(zai)局部注射經體(ti)(ti)(ti)外(wai)(wai)(wai)擴(kuo)增(zeng)(zeng)和(he)(he)誘(you)導(dao)向成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)樣細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)分化(hua)的(de)(de)(de)(de)自(zi)體(ti)(ti)(ti)BMSCs、混入凝血(xue)酶(mei)(thrombin)、鈣離子(calcium)的(de)(de)(de)(de)富含(han)血(xue)小(xiao)板的(de)(de)(de)(de)血(xue)漿(platelet-rich plasma ,PRP) ,可加快(kuai)成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)并安全微創;Morishita等(deng)(deng)(deng)(deng)[11]將自(zi)體(ti)(ti)(ti)BMSCs體(ti)(ti)(ti)外(wai)(wai)(wai)擴(kuo)增(zeng)(zeng)、成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)誘(you)導(dao),在(zai)2-4d分化(hua)為成(cheng)(cheng)(cheng)纖維細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)是(shi)與(yu)HA復(fu)合(he)(he)(he),經過4W增(zeng)(zeng)殖分化(hua),通過檢測(ce)(ce)證(zheng)(zheng)明(ming)(ming)成(cheng)(cheng)(cheng)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)構(gou)建(jian)了體(ti)(ti)(ti)外(wai)(wai)(wai)再(zai)生骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu),并用于(yu)3例(li)良(liang)(liang)性(xing)骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)腫瘤(liu)治療,術(shu)后(hou)(hou)影像(xiang)學(xue)(xue)結果(guo)顯示,骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)修(xiu)(xiu)復(fu)速度比文獻報(bao)道(dao)的(de)(de)(de)(de)單純HA明(ming)(ming)顯加快(kuai)。.此(ci)(ci)外(wai)(wai)(wai),組(zu)(zu)(zu)(zu)(zu)織(zhi)工(gong)程技術(shu)在(zai)口腔頜(he)面外(wai)(wai)(wai)科重建(jian)腭骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)[12]牙(ya)周組(zu)(zu)(zu)(zu)(zu)織(zhi)[7] 牙(ya)槽骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)裂(lie)成(cheng)(cheng)(cheng)型 [13] ,以及上頜(he)竇底加強 [14] 、牙(ya)槽骨(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)(gu)脊重建(jian) [15] 等(deng)(deng)(deng)(deng)都有(you)(you)報(bao)道(dao)。迄今, 臨床(chuang)(chuang)應用只(zhi)是(shi)一些(xie)零(ling)星報(bao)道(dao)和(he)(he)初步觀測(ce)(ce),對該技術(shu)臨床(chuang)(chuang)全面評價尚(shang)缺(que)乏足夠的(de)(de)(de)(de)資(zi)料[16]


2. 規模化臨床應用面臨的主要問題和對策 ?

2.1 ?目(mu)前制(zhi)約骨(gu)組(zu)(zu)織工程(cheng)臨(lin)(lin)床(chuang)規模化(hua)應(ying)用(yong)(yong)(yong)的(de)(de)(de)(de)是基(ji)(ji)(ji)(ji)礎研(yan)(yan)究(jiu)(jiu)的(de)(de)(de)(de)各個環(huan)節存(cun)(cun)在(zai)(zai)(zai)的(de)(de)(de)(de)技(ji)(ji)術(shu)瓶頸。 ? ? 首(shou)先(xian),目(mu)前開發(fa)(fa)的(de)(de)(de)(de)單(dan)一(yi)(yi)支架材料(liao)各有(you)(you)優缺點,如(ru)(ru)天然(ran)膠(jiao)原和(he)纖維蛋(dan)白(bai)(bai)(bai)凝膠(jiao)組(zu)(zu)織相(xiang)容性(xing)(xing)(xing)(xing)較好,但(dan)機械性(xing)(xing)(xing)(xing)能(neng)差;可(ke)降解是聚乳酸(suan)等(deng)(deng)人(ren)工材料(liao)優點,但(dan)親水(shui)性(xing)(xing)(xing)(xing)及組(zu)(zu)織相(xiang)容性(xing)(xing)(xing)(xing)差;以磷酸(suan)為(wei)基(ji)(ji)(ji)(ji)礎的(de)(de)(de)(de)骨(gu)水(shui)泥、陶瓷或生(sheng)(sheng)(sheng)物(wu)活性(xing)(xing)(xing)(xing)玻璃(li)等(deng)(deng)材料(liao)的(de)(de)(de)(de)生(sheng)(sheng)(sheng)物(wu)相(xiang)容性(xing)(xing)(xing)(xing)及骨(gu)傳(chuan)導性(xing)(xing)(xing)(xing)較好,但(dan)力(li)學性(xing)(xing)(xing)(xing)能(neng)差、易碎裂而不(bu)能(neng)滿足(zu)(zu)臨(lin)(lin)床(chuang)要(yao)求(qiu)。復(fu)合(he)材料(liao)性(xing)(xing)(xing)(xing)能(neng)一(yi)(yi)定程(cheng)度(du)上(shang)可(ke)產(chan)生(sheng)(sheng)(sheng)優勢互補,但(dan)距臨(lin)(lin)床(chuang)要(yao)求(qiu)存(cun)(cun)在(zai)(zai)(zai)差距。目(mu)前臨(lin)(lin)床(chuang)應(ying)用(yong)(yong)(yong)的(de)(de)(de)(de)主(zhu)(zhu)要(yao)是羥基(ji)(ji)(ji)(ji)磷灰石。其(qi)次(ci),細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)選(xuan)擇(ze)、培養(yang)等(deng)(deng)環(huan)節存(cun)(cun)在(zai)(zai)(zai)安(an)(an)全(quan)隱患。自(zi)體(ti)(ti)(ti)(ti)BMSCs的(de)(de)(de)(de)應(ying)用(yong)(yong)(yong)最貼近臨(lin)(lin)床(chuang),但(dan)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)在(zai)(zai)(zai)骨(gu)髓中(zhong)(zhong)含量極低(di)(0..003—0.015%) [17] ,必須先(xian)獲(huo)(huo) 取并在(zai)(zai)(zai)體(ti)(ti)(ti)(ti)外(wai)(wai)擴(kuo)增(zeng)(zeng),然(ran)而,研(yan)(yan)究(jiu)(jiu)表明最大24-40次(ci)倍增(zeng)(zeng)就會進(jin)入老化(hua)或生(sheng)(sheng)(sheng)長(chang)停(ting)滯期,從而限(xian)制(zhi)了(le)臨(lin)(lin)床(chuang)應(ying)用(yong)(yong)(yong)[18]。基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)工程(cheng)方(fang)法異(yi)(yi)(yi)位表達(da)端粒(li)酶反(fan)轉錄酶,可(ke)以消除(chu)(chu)因(yin)(yin)(yin)多次(ci)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)分(fen)裂引起染(ran)(ran)色體(ti)(ti)(ti)(ti)端粒(li)的(de)(de)(de)(de)縮(suo)短,細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)可(ke)無限(xian)分(fen)裂,從而無限(xian)延長(chang)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)壽命(ming) [19] ,但(dan)出(chu)(chu)于安(an)(an)全(quan)考慮只限(xian)于實(shi) 驗室(shi)。干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)從體(ti)(ti)(ti)(ti)內(nei)(nei)到體(ti)(ti)(ti)(ti)外(wai)(wai),細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)會出(chu)(chu)現(xian)(xian)行(xing)為(wei)變(bian)(bian)異(yi)(yi)(yi)與轉型(xing)[20],體(ti)(ti)(ti)(ti)外(wai)(wai)擴(kuo)增(zeng)(zeng)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)輸入體(ti)(ti)(ti)(ti)內(nei)(nei)后也(ye)(ye)會異(yi)(yi)(yi)常(chang)生(sheng)(sheng)(sheng)長(chang) [21] ,一(yi)(yi)項研(yan)(yan)究(jiu)(jiu)顯示(shi)鼠(shu)類(lei)的(de)(de)(de)(de)骨(gu)髓基(ji)(ji)(ji)(ji)質干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)經過(guo)體(ti)(ti)(ti)(ti)外(wai)(wai)長(chang)期培養(yang)后導致(zhi)染(ran)(ran)色體(ti)(ti)(ti)(ti)積累 損傷(shang)(shang),最后出(chu)(chu)現(xian)(xian)惡(e)變(bian)(bian)[22];細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)體(ti)(ti)(ti)(ti)外(wai)(wai)培養(yang)常(chang)規在(zai)(zai)(zai)培養(yang)液中(zhong)(zhong)加胎(tai)牛(niu)(niu)血清(qing),不(bu)可(ke)避(bi)免(mian)(mian)(mian)會傳(chuan)染(ran)(ran)疾病如(ru)(ru)瘋牛(niu)(niu)病[23]或由異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)蛋(dan)白(bai)(bai)(bai)觸發(fa)(fa)免(mian)(mian)(mian)疫(yi)(yi)(yi)反(fan)應(ying)[24]。此外(wai)(wai),也(ye)(ye)有(you)(you)研(yan)(yan)究(jiu)(jiu)者立足(zu)(zu)自(zi)體(ti)(ti)(ti)(ti)成(cheng)體(ti)(ti)(ti)(ti)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao),利用(yong)(yong)(yong)轉基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)技(ji)(ji)術(shu),將4種(zhong)(zhong)基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)[25]OCT4、NANOG、SOX2、LIN28或OCT3/4、SOX2、C-MYC和(he)KLF4 [26] 轉入到人(ren)的(de)(de)(de)(de)體(ti)(ti)(ti)(ti)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)中(zhong)(zhong),得到類(lei)似于胚胎(tai)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)的(de)(de)(de)(de)多能(neng)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao),增(zeng)(zeng)強(qiang)增(zeng)(zeng)殖分(fen)化(hua)能(neng)力(li), 滿足(zu)(zu)治療需要(yao),但(dan)潛在(zai)(zai)(zai)致(zhi)瘤風險只限(xian)于實(shi)驗室(shi)。自(zi)體(ti)(ti)(ti)(ti)來(lai)源(yuan)的(de)(de)(de)(de)種(zhong)(zhong)子(zi)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)不(bu)能(neng)用(yong)(yong)(yong)來(lai)儲(chu)備(bei)建(jian)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)庫(ku),急需時方(fang)可(ke)著(zhu)手(shou)準(zhun)備(bei),體(ti)(ti)(ti)(ti)外(wai)(wai)擴(kuo)增(zeng)(zeng)時間長(chang),患者不(bu)得不(bu)長(chang)時間等(deng)(deng)待。同種(zhong)(zhong)異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)可(ke)作(zuo)為(wei)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)庫(ku)種(zhong)(zhong)子(zi)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)預先(xian)儲(chu)備(bei),但(dan)是,除(chu)(chu)了(le)遇到與自(zi)體(ti)(ti)(ti)(ti)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)相(xiang)同培養(yang)問題外(wai)(wai),涉及更(geng)為(wei)復(fu)雜的(de)(de)(de)(de)免(mian)(mian)(mian)疫(yi)(yi)(yi)原性(xing)(xing)(xing)(xing)問題。研(yan)(yan)究(jiu)(jiu)發(fa)(fa)現(xian)(xian)基(ji)(ji)(ji)(ji)質干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)具有(you)(you)免(mian)(mian)(mian)疫(yi)(yi)(yi)調(diao)(diao)節作(zuo)用(yong)(yong)(yong)[27],包括促進(jin)I型(xing)輔助T細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)向(xiang)Ⅱ型(xing)轉變(bian)(bian)、下調(diao)(diao)NK細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)釋放干(gan)(gan)(gan)擾(rao)素--γ(IFN-γ)、和(he)B細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)合(he)成(cheng)抗體(ti)(ti)(ti)(ti),并且,為(wei)避(bi)免(mian)(mian)(mian)牛(niu)(niu)血清(qing)培養(yang)帶(dai)來(lai)風險,用(yong)(yong)(yong)人(ren)冰(bing)凍血漿 [28] 或血小板裂解液 [29] 代替(ti)牛(niu)(niu)血清(qing),發(fa)(fa)現(xian)(xian)不(bu)僅可(ke)提高增(zeng)(zeng)值(zhi)率,而且不(bu)改(gai)變(bian)(bian) 形態學、免(mian)(mian)(mian)疫(yi)(yi)(yi)表型(xing)和(he)分(fen)化(hua)能(neng)力(li),也(ye)(ye)沒有(you)(you)基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)異(yi)(yi)(yi)常(chang)[30、31]、并且保(bao)持(chi)了(le)免(mian)(mian)(mian)疫(yi)(yi)(yi)修飾,抑制(zhi)異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)蛋(dan)白(bai)(bai)(bai)導致(zhi)淋巴細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)增(zeng)(zeng)殖[32],對裸鼠(shu)不(bu)具致(zhi)瘤性(xing)(xing)(xing)(xing)[33],這為(wei)用(yong)(yong)(yong)異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)基(ji)(ji)(ji)(ji)質干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)作(zuo)為(wei)種(zhong)(zhong)子(zi)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)建(jian)庫(ku)提供支持(chi);另外(wai)(wai),研(yan)(yan)究(jiu)(jiu)發(fa)(fa)現(xian)(xian)CTLA4-Ig(cytotoxic T lymphocyte-associated antigen4-Ig)是一(yi)(yi)種(zhong)(zhong)融合(he)免(mian)(mian)(mian)疫(yi)(yi)(yi)球蛋(dan)白(bai)(bai)(bai),可(ke)以選(xuan)擇(ze)性(xing)(xing)(xing)(xing)地(di)阻(zu)斷CD28與B7的(de)(de)(de)(de)信號傳(chuan)導通(tong)路,阻(zu)斷T細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)殺傷(shang)(shang)作(zuo)用(yong)(yong)(yong)和(he)產(chan)生(sheng)(sheng)(sheng)免(mian)(mian)(mian)疫(yi)(yi)(yi)耐受(shou)。將CTLA4-Ig基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)轉到異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)MSCs,改(gai)變(bian)(bian)移(yi)(yi)植細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)的(de)(de)(de)(de)性(xing)(xing)(xing)(xing)狀,逃避(bi)或阻(zu)止(zhi)宿主(zhu)(zhu)識別,降低(di)異(yi)(yi)(yi)體(ti)(ti)(ti)(ti)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)免(mian)(mian)(mian)疫(yi)(yi)(yi)原性(xing)(xing)(xing)(xing),以此構建(jian)組(zu)(zu)織工程(cheng)骨(gu)成(cheng)功實(shi)現(xian)(xian)了(le)異(yi)(yi)(yi)位成(cheng)骨(gu) [34] ;除(chu)(chu)了(le)干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao) 外(wai)(wai),有(you)(you)研(yan)(yan)究(jiu)(jiu)證(zheng)明胎(tai)兒骨(gu)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)在(zai)(zai)(zai)免(mian)(mian)(mian)疫(yi)(yi)(yi)原性(xing)(xing)(xing)(xing)和(he)成(cheng)骨(gu)性(xing)(xing)(xing)(xing)能(neng)上(shang)優于骨(gu)髓干(gan)(gan)(gan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)[35],少量來(lai)源(yuan)就可(ke)滿足(zu)(zu)種(zhong)(zhong)子(zi)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)建(jian)庫(ku)需要(yao);以上(shang)發(fa)(fa)現(xian)(xian)有(you)(you)待于長(chang)期觀測論證(zheng)。第(di)三,目(mu)前構建(jian)的(de)(de)(de)(de)緩釋系統對成(cheng)骨(gu)因(yin)(yin)(yin)子(zi)緩釋不(bu)能(neng)完(wan)全(quan)模擬體(ti)(ti)(ti)(ti)內(nei)(nei)過(guo)程(cheng)。常(chang)用(yong)(yong)(yong)的(de)(de)(de)(de)一(yi)(yi)些(xie)基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)技(ji)(ji)術(shu)手(shou)段如(ru)(ru)轉基(ji)(ji)(ji)(ji)因(yin)(yin)(yin)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)移(yi)(yi)植或腺病毒轉染(ran)(ran)局(ju)部細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)在(zai)(zai)(zai)局(ju)部生(sheng)(sheng)(sheng)產(chan)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)因(yin)(yin)(yin)子(zi),有(you)(you)導致(zhi)免(mian)(mian)(mian)疫(yi)(yi)(yi)反(fan)應(ying)、傳(chuan)染(ran)(ran)疾病、細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)惡(e)變(bian)(bian)之嫌[22、23、24、35]。 。第(di)四,種(zhong)(zhong)植體(ti)(ti)(ti)(ti)在(zai)(zai)(zai)體(ti)(ti)(ti)(ti)內(nei)(nei)外(wai)(wai)構建(jian)過(guo)程(cheng)中(zhong)(zhong)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)生(sheng)(sheng)(sheng)存(cun)(cun)狀態不(bu)確定,因(yin)(yin)(yin)為(wei),細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)生(sheng)(sheng)(sheng)存(cun)(cun)要(yao)求(qiu)穩定外(wai)(wai)環(huan)境,包括溫度(du)、PH值(zhi)和(he)營養(yang)和(he)氧氣(qi)供應(ying) [37] ,體(ti)(ti)(ti)(ti)內(nei)(nei)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)和(he)毛(mao)細(xi)(xi)(xi)(xi)血管距離(li)20-200μm,細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)通(tong)過(guo)彌散(san) 獲(huo)(huo)取營養(yang)和(he)氧氣(qi)[38],在(zai)(zai)(zai)體(ti)(ti)(ti)(ti)外(wai)(wai),100-200μm距離(li)也(ye)(ye)可(ke)實(shi)現(xian)(xian)[39],細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)在(zai)(zai)(zai)體(ti)(ti)(ti)(ti)外(wai)(wai)三維結構中(zhong)(zhong),營養(yang)和(he)氧氣(qi)獲(huo)(huo)取困難,復(fu)合(he)細(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)(bao)的(de)(de)(de)(de)結構質量逐(zhu)漸下降[40、41、42、43];在(zai)(zai)(zai)靜態培養(yang)條件下發(fa)(fa)現(xian)(xian)三維支架

News / 推(tui)薦新聞 More
2020 - 09 - 07
我司同(tong)種異體骨植入材(cai)料(liao)產(chan)品延續注(zhu)冊(ce)已獲國(guo)(guo)(guo)家藥品監督管(guan)理(li)局批(pi)準(zhun),新(xin)注(zhu)冊(ce)證號及產(chan)品技術要(yao)求編號為國(guo)(guo)(guo)械注(zhu)準(zhun)20153131541,產(chan)品使用(yong)說明書和產(chan)品標簽同(tong)時(shi)做相應內(nei)容(rong)變更。以上變更自20200901及后(hou)續批(pi)次實施(shi),原(yuan)注(zhu)冊(ce)證號20153461541及注(zhu)冊(ce)產(chan)品標準(zhun)YZB/國(guo)(guo)(guo)2707-2015截至20200803批(pi)次不再(zai)使用(yong)。特此(ci)通知(zhi)!   杭州鴻立生物醫療科技有限公(gong)司2020年09月(yue)07日
2017 - 05 - 04
醫藥網訊(xun) 隨著社會老齡化加劇,居(ju)民健康意識覺醒,我國(guo)(guo)對骨科(ke)(ke)植入醫療(liao)器(qi)(qi)械(xie)的需求將延續增(zeng)(zeng)長(chang)(chang)。未來十(shi)年(nian)(nian)內(nei),我國(guo)(guo)有(you)望成(cheng)為全(quan)球骨科(ke)(ke)器(qi)(qi)械(xie)最大(da)市場,到(dao)(dao)2020年(nian)(nian)市場規(gui)模超過300億(yi)元。   在全(quan)球醫療(liao)器(qi)(qi)械(xie)領(ling)域,骨科(ke)(ke)器(qi)(qi)械(xie)是不容忽視(shi)的細分(fen)領(ling)域,占醫療(liao)器(qi)(qi)械(xie)市場規(gui)模比重達(da)到(dao)(dao)9%。盡管國(guo)(guo)內(nei)骨科(ke)(ke)器(qi)(qi)械(xie)行業(ye)處于(yu)(yu)發展初期,但(dan)增(zeng)(zeng)長(chang)(chang)迅猛,近(jin)五年(nian)(nian)來年(nian)(nian)復合(he)增(zeng)(zeng)長(chang)(chang)率達(da)到(dao)(dao)15.5%,遠(yuan)遠(yuan)超過全(quan)球4.5%增(zeng)(zeng)速。   所謂骨科(ke)(ke)植入醫療(liao)器(qi)(qi)械(xie),是用于(yu)(yu)人體骨骼(ge)替代(dai)、支撐、修補、填充的臨(lin)床骨科(ke)(ke)用醫療(liao)材料(liao)。從類(lei)(lei)別(bie)上可分(fen)四大(da)類(lei)(lei),即創傷(shang)、關(guan)(guan)節(jie)、脊(ji)柱和其他。其中(zhong),創傷(shang)、關(guan)(guan)節(jie)和脊(ji)柱類(lei)(lei)在骨科(ke)(ke)器(qi)(qi)械(xie)中(zhong)份額超過八成(cheng)。   我國(guo)(guo)骨科(ke)(ke)醫療(liao)器(qi)(qi)械(xie)行業(ye)始(shi)于(yu)(yu)上個(ge)世紀八十(shi)年(nian)(nian)代(dai),經過20余年(nian)(nian)發展,已培育出一(yi)批具有(you)較強(qiang)競爭力的本土(tu)企(qi)業(ye),但(dan)與國(guo)(guo)際領(ling)先企(qi)業(ye)相比,還有(you)較大(da)差(cha)距。   總體來看,國(guo)(guo)內(nei)骨科(ke)(ke)器(qi)(qi)械(xie)行業(ye)整體滲透率低,集中(zhong)在中(zhong)低端市場,企(qi)業(ye)規(gui)模...
2017 - 05 - 04
摘要(yao)  合(he)(he)(he)成材(cai)料(liao)組織(zhi)(zhi)工(gong)(gong)程骨(gu)(gu)移植物(wu)是(shi)(shi)當前骨(gu)(gu)移植材(cai)料(liao)研發(fa)重(zhong)點,發(fa)展迅速,但(dan)是(shi)(shi),目前研發(fa)的(de)(de)(de)各類支架材(cai)料(liao)性能(neng)存在(zai)(zai)缺陷,還(huan)不(bu)能(neng)完全滿足臨(lin)床(chuang)要(yao)求(qiu);細(xi)(xi)(xi)胞(bao)(bao)(bao)體(ti)(ti)外(wai)篩選、擴(kuo)增(zeng)、分(fen)(fen)化和為能(neng)在(zai)(zai)局部(bu)持續釋放細(xi)(xi)(xi)胞(bao)(bao)(bao)因(yin)子(zi)而采用(yong)的(de)(de)(de)轉(zhuan)基因(yin)細(xi)(xi)(xi)胞(bao)(bao)(bao)移植或腺病(bing)毒轉(zhuan)染局部(bu)細(xi)(xi)(xi)胞(bao)(bao)(bao)等(deng)(deng)技(ji)術還(huan)存在(zai)(zai)安(an)全隱患(huan),回植體(ti)(ti)內后不(bu)能(neng)保(bao)證細(xi)(xi)(xi)胞(bao)(bao)(bao)活性,細(xi)(xi)(xi)胞(bao)(bao)(bao)骨(gu)(gu)組織(zhi)(zhi)工(gong)(gong)程種植體(ti)(ti)構建質量、及(ji)時(shi)性,儲(chu)存、運輸(shu)等(deng)(deng)方面還(huan)不(bu)具臨(lin)床(chuang)規模化應用(yong)的(de)(de)(de)可行性。目前,無細(xi)(xi)(xi)胞(bao)(bao)(bao)人工(gong)(gong)合(he)(he)(he)成材(cai)料(liao)在(zai)(zai)臨(lin)床(chuang)上脊柱融合(he)(he)(he)、良(liang)性骨(gu)(gu)腫瘤刮(gua)除(chu)后填充等(deng)(deng)方面應用(yong)較普遍,細(xi)(xi)(xi)胞(bao)(bao)(bao)骨(gu)(gu)組織(zhi)(zhi)工(gong)(gong)程移植物(wu)應用(yong)僅(jin)見于散在(zai)(zai)病(bing)例報道(dao)。關鍵詞  骨(gu)(gu)組織(zhi)(zhi)工(gong)(gong)程;支架;干細(xi)(xi)(xi)胞(bao)(bao)(bao);細(xi)(xi)(xi)胞(bao)(bao)(bao)因(yin)子(zi);臨(lin)床(chuang)上嚴重(zhong)創傷、腫瘤切除(chu)、骨(gu)(gu)感染、骨(gu)(gu)壞死等(deng)(deng)原因(yin)導致的(de)(de)(de)的(de)(de)(de)骨(gu)(gu)缺損、骨(gu)(gu)折不(bu)愈合(he)(he)(he)以及(ji)人工(gong)(gong)假體(ti)(ti)置換(huan)及(ji)翻(fan)修、脊柱、關節融合(he)(he)(he)等(deng)(deng)十分(fen)(fen)常見,自體(ti)(ti)皮質-松質骨(gu)(gu)移植仍是(shi)(shi)無法被替代的(de)(de)(de)“金標準”,但(dan)是(shi)(shi),存在(zai)(zai)諸如(ru)供區(qu)新(xin)的(de)(de)(de)創傷、感染、疼痛等(deng)(deng)并發(fa)癥,特(te)別(bie)是(shi)(shi),來源有限不(bu)能(neng)滿足臨(lin)床(chuang)需(xu)...
2017 - 05 - 04
大(da)段(duan)骨(gu)(gu)(gu)(gu)(gu)缺損是矯(jiao)形(xing)外(wai)科(ke)較(jiao)普遍又棘手(shou)(shou)的問題(ti),由于自體(ti)骨(gu)(gu)(gu)(gu)(gu)來源有限,人(ren)工假體(ti)無生(sheng)物學(xue)活性,易(yi)發(fa)生(sheng)松動(dong)和(he)疲勞(lao)斷裂等并(bing)發(fa)癥,而(er)異(yi)體(ti)骨(gu)(gu)(gu)(gu)(gu)來源豐富,形(xing)狀大(da)小不受(shou)限制,并(bing)具有生(sheng)物學(xue)活性,有較(jiao)好的應(ying)用前景。臨(lin)床(chuang)(chuang)長期隨訪(fang)結(jie)果常發(fa)生(sheng)異(yi)體(ti)骨(gu)(gu)(gu)(gu)(gu)骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)并(bing)發(fa)癥〔1,2〕,影響手(shou)(shou)術效果。為此本文(wen)著重闡述骨(gu)(gu)(gu)(gu)(gu)腫瘤保(bao)肢術后(hou)(hou)發(fa)生(sheng)異(yi)體(ti)骨(gu)(gu)(gu)(gu)(gu)骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)的臨(lin)床(chuang)(chuang)特(te)(te)點(dian)及(ji)預防措施,以(yi)提高(gao)保(bao)肢手(shou)(shou)術質量。  1 同種異(yi)體(ti)骨(gu)(gu)(gu)(gu)(gu)骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)的臨(lin)床(chuang)(chuang)與(yu)治療  1.1 臨(lin)床(chuang)(chuang)特(te)(te)點(dian) 保(bao)肢術后(hou)(hou)異(yi)體(ti)骨(gu)(gu)(gu)(gu)(gu)骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)的發(fa)生(sheng)率(lv)(lv)占16.6%~19%〔1~3〕,多(duo)見于術后(hou)(hou)6~100個月(yue),高(gao)峰位于術后(hou)(hou)6~18個月(yue),2年內(nei)發(fa)生(sheng)率(lv)(lv)占53%以(yi)上(shang),3年內(nei)所占比(bi)例超(chao)過(guo)70%〔1〕。術后(hou)(hou)是否存(cun)在宿主與(yu)供體(ti)結(jie)合部(bu)骨(gu)(gu)(gu)(gu)(gu)不連與(yu)骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)無關,擔骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)發(fa)生(sheng)后(hou)(hou),受(shou)供體(ti)結(jie)合部(bu)愈合率(lv)(lv)有所減低〔1,4〕。  1.2 分類(lei) 1990年Berrey等〔1〕將骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)分為三型(xing)。Ⅰ型(xing)——不是由于感染、腫痛復發(fa)而(er)導致的迅速、幾(ji)乎完全的移植骨(gu)(gu)(gu)(gu)(gu)溶解、病理(li)性骨(gu)(gu)(gu)(gu)(gu)折(zhe)(zhe)。可...
Copyright ? 2016 - 2019杭州鴻立生物(wu)醫(yi)療科技(ji)有(you)限公司
犀(xi)牛云提供企業云服務
地(di)址(zhi):杭州經濟技術開(kai)發區(qu)白楊(yang)街道21號大街600號(海外留學生創業園(yuan)2幢3樓)
電話:0571-87703032 
傳真(zhen):0571-87703031
郵編:330520